Drug Profile
BIIB 022
Alternative Names: Anti-IGF-1R monoclonal antibody - Biogen; BIIB-022Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Biogen
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Liver cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for phase-I development in liver cancer(Combination therapy, Late-stage disease) in Singapore (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in liver cancer(Combination therapy, Late-stage disease) in Taiwan (IV, Infusion)